Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27685
Title: | Effects of daily iron supplementation in 2- to 5-year-old children: Systematic review and meta-analysis. | Authors: | Pasricha S.-R.;Biggs B.-A.;Thompson J. | Institution: | (Thompson) School of Medicine, Faculty of Health Sciences, University of Adelaide, SA, Australia (Biggs, Pasricha) Department of Medicine, University of Melbourne, Victorian Infectious Diseases Service, Parkville, VIC, Australia (Pasricha) Nossal Institute for Global Health, Monash Medical Centre, University of Melbourne, Carlton, VIC 3010, Australia (Pasricha) Thalassaemia Service, Monash Medical Centre, VIC, Australia | Issue Date: | 29-Apr-2013 | Copyright year: | 2013 | Publisher: | American Academy of Pediatrics (141 Northwest Point Blvd, P.O. Box 927, Elk Grove Village IL 60007-1098, United States) | Place of publication: | United States | Publication information: | Pediatrics. 131 (4) (pp 739-753), 2013. Date of Publication: April 2013. | Abstract: | BACKGROUND AND OBJECTIVES: Iron deficiency (ID) is the most common cause of anemia worldwide. The prevalence is highest among preschool-aged children. Iron is widely administered to children with or at risk for ID, but evidence of benefit among 2- to 5-year-old children has not been evaluated by systematic review. We summarize the evidence for the benefit and safety of daily iron supplementation with regard to hematologic, growth, and cognitive parameters in 2 to 5 year olds. METHOD(S): Electronic databases, regional databases, thesis repositories, gray literature, and references of studies and previous reviews were searched. We included randomized controlled trials that compared daily oral iron supplementation with control in 2 to 5 year olds. A random-effects meta-analysis was used to synthesize predefined outcomes reported by at least 2 studies. RESULT(S): Of 9169 references, 15 studies met the inclusion criteria, none of which were at low risk of bias. Children receiving iron supplementation had a mean end point hemoglobin of 6.97 g/L (P <.00001; I2 = 82%) greater than controls, whereas mean end point ferritin was 11.64 mg/L (P <.0001; I2 = 48%) greater. No trials reported the effects of iron supplementation on ID or iron deficiency anemia, and only one reported on anemia. Limited evidence suggested that iron supplementation produced a small improvement in cognitive development but had no effect on physical growth. CONCLUSION(S): In 2 to 5 year olds, daily iron supplementation increases hemoglobin and ferritin. There is a concerning lack of data on the effect of iron supplementation on clinically important outcomes including anemia, ID anemia, ID, and cognitive development. Additional interventional studies in this age group are needed. Copyright © 2013 by the American Academy of Pediatrics. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1542/peds.2012-2256 | PubMed URL: | 23478873 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23478873] | ISSN: | 0031-4005 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27685 | Type: | Review | Subjects: | systematic review albendazole/ct [Clinical Trial] albendazole/cb [Drug Combination] ascorbic acid/ct [Clinical Trial] ascorbic acid/cb [Drug Combination] cyanocobalamin/ct [Clinical Trial] cyanocobalamin/cb [Drug Combination] edetate iron/ct [Clinical Trial] ferric ammonium citrate/ct [Clinical Trial] ferric ammonium citrate/cb [Drug Combination] ferric ammonium citrate/dt [Drug Therapy] ferritin/ec [Endogenous Compound] ferrous sulfate/ct [Clinical Trial] ferrous sulfate/cb [Drug Combination] ferrous sulfate/dt [Drug Therapy] folic acid/ct [Clinical Trial] folic acid/cb [Drug Combination] hemoglobin/ec [Endogenous Compound] *iron/ct [Clinical Trial] *iron/dt [Drug Therapy] *iron/po [Oral Drug Administration] mebendazole/ct [Clinical Trial] mebendazole/cb [Drug Combination] multivitamin/ct [Clinical Trial] multivitamin/cb [Drug Combination] placebo pyrimethamine/ct [Clinical Trial] pyrimethamine/cb [Drug Combination] retinol/ct [Clinical Trial] retinol/cb [Drug Combination] sulfadoxine/ct [Clinical Trial] sulfadoxine/cb [Drug Combination] transferrin/ec [Endogenous Compound] zinc/ct [Clinical Trial] zinc/cb [Drug Combination] iron deficiency/dt [Drug Therapy] anemia/dt [Drug Therapy] cognitive development drug safety growth hematocrit human infection iron deficiency anemia/dt [Drug Therapy] *iron therapy mean corpuscular volume meta analysis priority journal randomized controlled trial (topic) review *iron therapy mean corpuscular volume meta analysis priority journal randomized controlled trial (topic) review anemia / drug therapy systematic review cognitive development drug safety growth hematocrit human infection iron deficiency / drug therapy iron deficiency anemia / drug therapy |
Type of Clinical Study or Trial: | Systematic review and/or meta-analysis |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.